Key result
Intravenous morphine use in acute coronary syndrome is associated with delayed antiplatelet absorption, larger infarct sizes, and potentially increased mortality across multiple reviewed studies.
Why the study?
Does intravenous morphine increase adverse outcomes in patients with acute coronary syndrome?
Population
Patients with acute coronary syndrome (ACS) experiencing chest pain
Comparison
Intravenous (IV) morphine vs No morphine or placebo
Design
Review
Authors
Loading...
May warrant caution with IV morphine in ACS; leaves open need for RCTs on hard outcomes.
Does intravenous morphine increase adverse outcomes in patients with acute coronary syndrome?
Intravenous morphine for chest pain in ACS may lead to delayed antiplatelet absorption and larger infarct sizes, challenging its routine use as recommended by current guidelines.
Chen et al. (2018) conducted a review in Acute Coronary Syndrome. Intravenous morphine vs. No morphine or placebo was evaluated. Intravenous morphine use in acute coronary syndrome is associated with delayed antiplatelet absorption, larger infarct sizes, and potentially increased mortality across multiple reviewed studies.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: